DNA Script Appoints Chris Barbazette as Chief Commercial Officer

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, has added life sciences veteran Chris Barbazette as Chief Commercial Officer to its leadership team.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, May 10, 2022
Information
Tags: 
Science, Other Science, Biotechnology, Research, Health, Technology, Genetics, Other Technology, Senior, Enzyme, SYNTAX, EDS, Organization, Affymetrix, Thermo Fisher Scientific, Synthetic biology, Chief commercial officer, DNA, Innovation, Genomics, Organic acid, Marketing, View, CEO, Technology, Research, Acquisition, Multimedia, Fine chemical, Management
Geotags: 
UNITED STATES, NORTH AMERICA, CALIFORNIA
⚠ generated by AI ↴
Organisation: 
DNA SCRIPT
Summary
Key Points: 
  • DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, has added life sciences veteran Chris Barbazette as Chief Commercial Officer to its leadership team.
  • View the full release here: https://www.businesswire.com/news/home/20220510005578/en/
    Chris Barbazette appointed Chief Commercial Officer of DNA Script (Photo: Business Wire)
    We are excited to welcome Chris to the DNA Script family, said CEO and co-founder Thomas Ybert.
  • I look forward to working with Chris as DNA Script continues to rapidly scale to meet demand for the SYNTAX Platform.
  • Barbazette joins DNA Script from Resolve Biosciences, an emerging leader in spatial biology, where he served as Chief Commercial Officer and established the German parent companys U.S. headquarters.


DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, has added life sciences veteran Chris Barbazette as Chief Commercial Officer to its leadership team. In his new position, Barbazette will be responsible for leading DNA Script’s marketing, sales, and support teams and will play a pivotal role in building upon the company’s market position to drive continued commercial growth, as well as investor and customer value.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510005578/en/

Chris Barbazette appointed Chief Commercial Officer of DNA Script (Photo: Business Wire)

Chris Barbazette appointed Chief Commercial Officer of DNA Script (Photo: Business Wire)

“We are excited to welcome Chris to the DNA Script family,” said CEO and co-founder Thomas Ybert. “Chris has an incredible wealth of experience bringing disruptive technologies to market on a global scale in both small and large organizations. I look forward to working with Chris as DNA Script continues to rapidly scale to meet demand for the SYNTAX Platform.”

Barbazette joins DNA Script from Resolve Biosciences, an emerging leader in spatial biology, where he served as Chief Commercial Officer and established the German parent company’s U.S. headquarters. In this role Barbazette developed the commercial strategy, led the development of the company’s branding, and built out front line sales, support, and marketing teams. Prior to Resolve Biosciences, Barbazette served in senior and executive leadership roles across several life science and diagnostic companies, including Genapsys and Agendia. At Affymetrix, he rose through several senior positions from 2007 and 2016, owning management of sales, marketing and support teams and commercial responsibilities across several continents until landing as Senior Vice President of Global Commercial Operations, where he aided in transitioning the commercial organization into Thermo Fisher Scientific following the company’s acquisition for $1.4 billion.

“I believe that DNA Script is at an inflection point with a disruptive technology to change the way the market operates. I want to lead the company to further customer centricity in application areas like synthetic biology, genomics and personalized medicine, where there is an unmet need for fast and on-demand custom solutions, ” said Barbazette. “I look forward to working alongside this highly talented and strong leadership team to build a global, world-class commercial organization.”

About DNA Script

Founded in 2014, DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, allowing this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy. www.dnascript.com

Copyright: 
Copyright Business Wire 2022